ERBB2 and gastric cancer: A comprehensive network meta-analysis led by Zhang et al., which included 7898 patients across eight trials, identified cadonilimab plus chemotherapy as a leading treatment option for HER2-negative advanced gastric cancer, especially in PD-L1 CPS-positive patients [17].